A Promising Drug for the Treatment of Severe Lung Inflammation in COVID-19 Patients.

[2greys]

Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19 and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab, may prevent the “cytokine storm” that inflames and fatally damages the lungs and other organs of many COVID-19 patients.

Harish Seethamraju, M.D., an organ transplant specialist and a member of the department of medicine at Montefiore and Einstein, researched leronlimab early in the pandemic and realized its potential for treating his transplant patients who had COVID-19. He then obtained “compassionate use” permission from the Food and Drug Administration so that he and his colleagues could use leronlimab on 10 severely ill COVID-19 patients, six of them transplant patients from various organ transplant programs.

brcacommunitystudy.einstein...

[Kristicats]

Let’s hope also with all this research going on Re lungs that we may benefit after this virus has gone,